BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

882 related articles for article (PubMed ID: 17531573)

  • 1. Measuring aspirin resistance, clopidogrel responsiveness, and postprocedural markers of myonecrosis in patients undergoing percutaneous coronary intervention.
    Buch AN; Singh S; Roy P; Javaid A; Smith KA; George CE; Pichard AD; Satler LF; Kent KM; Suddath WO; Waksman R
    Am J Cardiol; 2007 Jun; 99(11):1518-22. PubMed ID: 17531573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment.
    Chen WH; Lee PY; Ng W; Tse HF; Lau CP
    J Am Coll Cardiol; 2004 Mar; 43(6):1122-6. PubMed ID: 15028378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) study.
    Patti G; Nusca A; Mangiacapra F; Gatto L; D'Ambrosio A; Di Sciascio G
    J Am Coll Cardiol; 2008 Sep; 52(14):1128-33. PubMed ID: 18804738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relation of troponin I levels following nonemergent percutaneous coronary intervention to short- and long-term outcomes.
    Feldman DN; Minutello RM; Bergman G; Moussa I; Wong SC
    Am J Cardiol; 2009 Nov; 104(9):1210-5. PubMed ID: 19840564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance.
    Lev EI; Patel RT; Maresh KJ; Guthikonda S; Granada J; DeLao T; Bray PF; Kleiman NS
    J Am Coll Cardiol; 2006 Jan; 47(1):27-33. PubMed ID: 16386660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relation of low response to clopidogrel assessed with point-of-care assay to periprocedural myonecrosis in patients undergoing elective coronary stenting for stable angina pectoris.
    Cuisset T; Hamilos M; Sarma J; Sarno G; Wyffels E; Vanderheyden M; Barbato E; Bartunek J; De Bruyne B; Wijns W
    Am J Cardiol; 2008 Jun; 101(12):1700-3. PubMed ID: 18549843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Usefulness of aspirin resistance after percutaneous coronary intervention for acute myocardial infarction in predicting one-year major adverse coronary events.
    Marcucci R; Paniccia R; Antonucci E; Gori AM; Fedi S; Giglioli C; Valente S; Prisco D; Abbate R; Gensini GF
    Am J Cardiol; 2006 Nov; 98(9):1156-9. PubMed ID: 17056317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relation of endothelial function to residual platelet reactivity after clopidogrel in patients with stable angina pectoris undergoing percutaneous coronary intervention.
    Muller O; Hamilos M; Bartunek J; Ulrichts H; Mangiacapra F; Holz JB; Ntalianis A; Trana C; Dierickx K; Vercruysse K; De Bruyne B; Wijns W; Barbato E
    Am J Cardiol; 2010 Feb; 105(3):333-8. PubMed ID: 20102944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Point-of-care assessment of platelet reactivity after clopidogrel to predict myonecrosis in patients undergoing percutaneous coronary intervention.
    Mangiacapra F; Barbato E; Patti G; Gatto L; Vizzi V; Ricottini E; D'Ambrosio A; Wijns W; Di Sciascio G
    JACC Cardiovasc Interv; 2010 Mar; 3(3):318-23. PubMed ID: 20298992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term clinical outcome based on aspirin and clopidogrel responsiveness status after elective percutaneous coronary intervention: a 3T/2R (tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel) trial substudy.
    Campo G; Fileti L; de Cesare N; Meliga E; Furgieri A; Russo F; Colangelo S; Brugaletta S; Ferrari R; Valgimigli M;
    J Am Coll Cardiol; 2010 Oct; 56(18):1447-55. PubMed ID: 20951320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical relevance of clopidogrel unresponsiveness during elective coronary stenting: experience with the point-of-care platelet function assay-100 C/ADP.
    Moerenhout CM; Claeys MJ; Haine S; Miljoen H; Bosmans JM; Vertessen F; Kluppels K; Van der Planken M; Vrints CJ
    Am Heart J; 2010 Mar; 159(3):434-8. PubMed ID: 20211306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of statins prior to percutaneous coronary intervention reduces myonecrosis and improves clinical outcome.
    Chang SM; Yazbek N; Lakkis NM
    Catheter Cardiovasc Interv; 2004 Jun; 62(2):193-7. PubMed ID: 15170709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized trial comparing 600- with 300-mg loading dose of clopidogrel in patients with non-ST elevation acute coronary syndrome undergoing percutaneous coronary intervention: results of the Platelet Responsiveness to Aspirin and Clopidogrel and Troponin Increment after Coronary intervention in Acute coronary Lesions (PRACTICAL) Trial.
    Yong G; Rankin J; Ferguson L; Thom J; French J; Brieger D; Chew DP; Dick R; Eccleston D; Hockings B; Walters D; Whelan A; Eikelboom JW
    Am Heart J; 2009 Jan; 157(1):60.e1-9. PubMed ID: 19081397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Occurrence of non-Q wave myocardial infarction following percutaneous coronary intervention in the stent era: systematic monitoring of the three markers of myocardial necrosis.
    Varani E; Balducelli M; Vecchi G; Gatti C; Lucchi GR; Maresta A
    J Interv Cardiol; 2005 Aug; 18(4):243-8. PubMed ID: 16115152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relation of aspirin resistance to coronary flow reserve in patients undergoing elective percutaneous coronary intervention.
    Chen WH; Lee PY; Ng W; Kwok JY; Cheng X; Lee SW; Tse HF; Lau CP
    Am J Cardiol; 2005 Sep; 96(6):760-3. PubMed ID: 16169354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlations between cardiac troponin I, cardiac troponin T, and creatine phosphokinase MB elevation following successful percutaneous coronary intervention and prognostic value of each marker.
    Okmen E; Kasikcioglu H; Sanli A; Uyarel H; Cam N
    J Invasive Cardiol; 2005 Feb; 17(2):63-7. PubMed ID: 15687525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up.
    Marcucci R; Gori AM; Paniccia R; Giusti B; Valente S; Giglioli C; Buonamici P; Antoniucci D; Abbate R; Gensini GF
    Circulation; 2009 Jan; 119(2):237-42. PubMed ID: 19118249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Usefulness of platelet response to clopidogrel by point-of-care testing to predict bleeding outcomes in patients undergoing percutaneous coronary intervention (from the Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty-Bleeding Study).
    Patti G; Pasceri V; Vizzi V; Ricottini E; Di Sciascio G
    Am J Cardiol; 2011 Apr; 107(7):995-1000. PubMed ID: 21256470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevated plasma fibrinogen rather than residual platelet reactivity after clopidogrel pre-treatment is associated with an increased ischemic risk during elective percutaneous coronary intervention.
    Ang L; Thani KB; Ilapakurti M; Lee MS; Palakodeti V; Mahmud E
    J Am Coll Cardiol; 2013 Jan; 61(1):23-34. PubMed ID: 23287370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Study on the relationship between aspirin resistance and incidence of myonecrosis after non-emergent percutaneous coronary intervention].
    Zhang Y; Liang J; Zhou YJ; Yuan H; Zhang YZ; Dong L
    Zhonghua Xin Xue Guan Bing Za Zhi; 2005 Aug; 33(8):695-9. PubMed ID: 16188050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.